Merck & Co., Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRK research report →
About the company
Merck & Co. , Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health.
- CEO
- Robert Davis
- IPO
- 1978
- Employees
- 73,000
- HQ
- Rahway, NJ, US
Price Chart
- Market Cap
- $294.03B
- P/E
- 32.94
- P/S
- 4.48
- P/B
- 6.41
- EV/EBITDA
- 19.56
- Div Yield
- 2.82%
- Gross Margin
- 75.91%
- Op Margin
- 27.59%
- Net Margin
- 13.62%
- ROE
- 17.93%
- ROIC
- 13.34%
- Revenue
- $64.93B · 1.18%
- Net Income
- $18.25B · 6.64%
- EPS
- $7.30 · 7.99%
- Op Income
- $23.49B
- FCF YoY
- -31.70%
- 52W High
- $125.14
- 52W Low
- $76.66
- 50D MA
- $116.18
- 200D MA
- $104.78
- Beta
- 0.22
- Avg Volume
- 9.84M
Get TickerSpark's AI analysis on MRK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 29, 26 | Warden Kathy J | other | 1,853.1 |
| May 29, 26 | Karsanbhai Surendralal Lanca | other | 1,853.1 |
| May 29, 26 | Coe Mary Ellen | other | 1,853.1 |
| May 29, 26 | THULIN INGE G | other | 1,853.1 |
| May 29, 26 | Seidman Christine E | other | 1,853.1 |
| May 29, 26 | RUSSO PATRICIA F | other | 1,853.1 |
| May 29, 26 | Rothman Paul | other | 1,853.1 |
| May 29, 26 | Mayo Stephen | other | 1,853.1 |
| May 29, 26 | LAVIZZO-MOUREY RISA J | other | 1,853.1 |
| May 29, 26 | GLOCER THOMAS H | other | 1,853.1 |
Our MRK coverage
Recent articles, reports, and earnings notes.
Merck & Company (MRK): KEYTRUDA Strength Meets Pipeline Diversification
Merck combines elite cash generation with a growing pipeline, but KEYTRUDA still drives nearly half of sales. The stock looks like a quality compounder as new launches help reduce concentration risk.
Merck’s latest data may have bought it more time than bears want to admit
Merck’s patent-cliff problem is real, but the market is acting like the runway ends tomorrow when the core franchise is still expanding today. Fresh lung-cancer data, rising Keytruda sales, and a packed oncology catalyst calendar make MRK look stronger than the fear trade suggests.
Merck & Co., Inc. (MRK) rises 5.6% on oncology wins
Merck & Co., Inc. (MRK) rises after positive Phase 3 lung cancer data and a favorable European regulatory opinion for a Keytruda regimen. The move reflects renewed confidence in Merck’s oncology pipeline and its ability to extend growth beyond Keytruda alone.
Want a deeper read on MRK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.